Our follow-on program, ARN, is derived from a novel family of global FAAH inhibitors and is in development for the treatment of social anxiety disorder and autism spectrum disorder.
ARN is designed to block the FAAH enzyme, similar to EX937, thereby preventing degradation of anandamide and leading to increased receptor signaling. In contrast to EX937, the ARN readily enter the CNS, which enables treatment of neurological disorders such as anxiety, autism, addiction and insomnia.
Published data for the ARN parent molecule, EX597, including work from international academic research laboratories, can be found here.